Articles of note for people dealing with pituitary disease and related conditions.
The latest from pharmaceutical companies and healthcare organizations
Brief, insightful commentary from Dr. Lewis Blevins on issues of relevance to pituitary disease.
Blaming it all, or nothing, on the pituitary
From Linda M. Rio, PWN contributor, author, and Marriage and Family Therapist: Last week, I experienced two note worthy experiences
Help us with our mission and win this beautiful oil on canvas painting. Here’s how.
When you donate $50.00 or more between now and September 30 you'll be automatically entered to win this great original oil on canvas painting by Dr. Lewis Blevins valued at $2,500. Every dollar contributes directly to our mission to inform and educate so more people are diagnosed properly and early.
Worth noting:
Camurus announces final results for the once-monthly octreotide subcutaneous treatment option for acromegaly. Read more
News from Recordati on osilodrostat for endogenous Cushing’s – More details here
Corcept Therapeutics reports significant results in Cushing’s drug trial. Read more
New support site from Chiesi; Rethink acromegaly
Crinetics Pharmaceuticals announces more Phase 3 paltusotine results in participants with acromegaly who were not pharmacologically treated . Read more
Pfizer announces Together with Acromegaly patient support site and Together for Rare: Understanding your insurance options video.
Chiesi relaunches a patient-facing website for Mycapssa.
Content for physicians and healthcare professionals.
Join a drug trial. Find out how. Here’s a partial list of studies.
Latest trends and a roundup of health and wellness news
The Podcast
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Live Talk on Demand
Today's podcast covers my conversation with Jill Sisco, president of the Acromegaly Community, about the recent meetings with the Food and Drug Administration (FDA), the US governmental entity responsible for approving new medications. Our conversation focuses on the original meeting held in 2021 and a recent listening session where the AC provided additional feedback to the FDA.
Apple Podcasts
Spotify
Amazon Music
Google Podcasts
